We read with great interest the article entitled “Efficacy of citalopram on stroke
recurrence: A randomized clinical trial” conducted by Çetin E. et al. [
[1]
]. This randomized clinical trial, in which 440 patients were enrolled, revealed a
significant relationship between depression treatment and recurrent stroke and patients
whose depression did not respond well to citalopram had 2.5 times higher chance of
stroke recurrence than the patients with remitting depression. Additionally, other
vascular risk factors (e.g. hypertension, atrial fibrillation, etc.) were shown as
predictors of stroke recurrence based on multivariable analysis. This study could
add valuable pieces to the current evidence regarding stroke secondary prevention;
however, some points exist in the aim, methods, results, and conclusion that should
be addressed.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Clinical NeuroscienceAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Efficacy of citalopram on stroke recurrence: A randomized clinical trial.J Clin Neurosci. 2022; 101: 168-174
- Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS).Stroke. 2018; 49: 2568-2576
- Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial.Lancet. 2019; 393: 265-274
- Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration.Stroke. 2021; 52: 2502-2509
- Effects of Fluoxetine on Outcomes at 12 Months after Acute Stroke.Stroke. 2021; 52: 3082-3087
- Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.Cochrane Database Syst Rev. 2019; 2019
- Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.Cochrane Database Syst Rev. 2021; 11
- Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial.Lancet Neurol. 2020; 19: 661-669
- Safety and Efficacy of SSRIs in Improving Poststroke Recovery: A Systematic Review and Meta-Analysis.J Am Heart Assoc. 2022; 11: e025868
- Effect of fluoxetine on three-year recurrence in acute ischemic stroke: A randomized controlled clinical study.Clin Neurol Neurosurg. 2018; 168: 1-6
- Recurrent Ischemic Stroke – A Systematic Review and Meta-Analysis.J Stroke Cerebrovasc Dis. 2021; 30105935
Article info
Publication history
Published online: February 23, 2023
Accepted:
February 15,
2023
Received:
February 8,
2023
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 Elsevier Ltd. All rights reserved.
